Thrombosis and anticoagulation.

abstract：:This article summarizes clinical results of the Intergroupe Francophone du Myélome (IFM) trials: high-dose therapy (HDT) supported with autologous stem cells improves survival, melphalan 200 mg/m(2) is the best preparative regimen, unpurged peripheral blood stem cells (PBSC) are the recommended source of stem cells to...

journal_title：Seminars in hematology

authors： Attal M,Harousseau JL

更新日期：2001-07-01 00:00:00

abstract：:Indolent non-Hodgkin lymphoma (NHL) comprises a group of incurable, generally slow-growing lymphomas highly responsive to initial therapy, with a relapsing and progressive course. Rituximab, an anti-CD20 antibody, has had a large impact on the treatment of indolent NHL. Its effectiveness as a single agent and in conju...

journal_title：Seminars in hematology

authors： Sousou T,Friedberg J

更新日期：2010-04-01 00:00:00

abstract：:Cyclic neutropenia is a rare hematologic disorder, characterized by repetitive episodes of fever, mouth ulcers, and infections attributable to recurrent severe neutropenia. Fluctuations in blood cells are due to oscillatory production of cells by the bone marrow. Recent genetic, molecular, and cellular studies have sh...

journal_title：Seminars in hematology

authors： Dale DC,Bolyard AA,Aprikyan A

更新日期：2002-04-01 00:00:00

abstract：:The purpose of this study was to assess the efficacy and side effect profile of the repeated use of anti-D for the treatment of pediatric immune thrombocytopenia (ITP) in a large pediatric hematology center. We performed a retrospective analysis of patient records for children (aged 4 months-18 years) treated for ITP ...

journal_title：Seminars in hematology

authors： Yacobovich J,Abu-Ahmed S,Steinberg-Shemer O,Goldberg T,Cohen M,Tamary H

更新日期：2016-04-01 00:00:00

abstract：:Current therapeutic strategies for autoimmune diseases primarily rely on immunosuppression, but global immune suppression results in an increased risk for severe infection and malignancy. In contrast, immuomodulation is another therapeutic approach employing intrinsic or environmental regulators that exert modulatory ...

journal_title：Seminars in hematology

authors： Kuwana M

更新日期：2016-04-01 00:00:00

abstract：:This phase I trial of idarubicin (IDA) was conducted in 32 patients with acute leukemia and chronic myelogenous leukemia (CML) in blastic crisis (CML/BC) who either had failed to achieve a complete remission (CR) after initial induction therapy or had relapsed after CR. IDA was administered at dosages ranging from an ...

journal_title：Seminars in hematology

authors： Tamura K

更新日期：1996-10-01 00:00:00

abstract：:Untreated anemia is common in cancer patients. Previous studies have demonstrated that both the existence of cancer and treatment with chemotherapy can suppress the normal endogenous erythropoietic response to anemia, making some cancer patients transfusion cadidates. In placebo-controlled phase III studies, administr...

journal_title：Seminars in hematology

authors： Glaspy J

更新日期：1997-07-01 00:00:00

abstract：:Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) (non-del(5q...

journal_title：Seminars in hematology

authors： Talati C,Sallman D,List A

更新日期：2017-07-01 00:00:00

abstract：:A number of human disorders, dubbed ribosomopathies, are linked to impaired ribosome biogenesis or function. These include but are not limited to Diamond Blackfan anemia (DBA), Shwachman Diamond syndrome (SDS), and the 5q- myelodysplastic syndrome (MDS). This review focuses on the latter two non-DBA disorders of ribos...

journal_title：Seminars in hematology

authors： Burwick N,Shimamura A,Liu JM

更新日期：2011-04-01 00:00:00

abstract：:In early studies, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to reduce the depth and duration of granulocytopenia in the settings of cancer chemotherapy and autologous bone marrow transplantation. In patients with myelodysplastic syndrome or aplastic anemia. GM-CSF has p...

journal_title：Seminars in hematology

authors： Gutterman J,Vadhan-Raj S,Logothetis C,Anaissle E,Estey E,Talpaz M,Kurzrock R

更新日期：1990-07-01 00:00:00

abstract：:Thrombus forms on catheters and other indwelling synthetic materials. Systemic heparin infusion decreases, but does not eliminate thrombus formation. The day is approaching when systemic heparinization may no longer be indicated to suppress catheter thrombogenesis. Passivation of catheters by heparin immobilization is...

journal_title：Seminars in hematology

authors： Eberhart RC,Clagett CP

更新日期：1991-10-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a complex and heterogeneous disease with distinct age-associated genomic and epigenomic alterations. A large number of somatic karyotypic and molecular alterations have been identified in AML to date; however, very few predict outcome or identify potential therapeutic targets. Here we d...

journal_title：Seminars in hematology

authors： Schuback HL,Arceci RJ,Meshinchi S

更新日期：2013-10-01 00:00:00

abstract：:It is now well accepted that a subgroup of patients with myelodysplastic syndromes (MDS) can recover from pancytopenia following immunosuppressive treatment (IST). For many years immunosuppression with antilymphocyte antibodies has been a standard treatment approach for patients with severe aplastic anemia (SAA). The ...

journal_title：Seminars in hematology

authors： Parikh AR,Olnes MJ,Barrett AJ

更新日期：2012-10-01 00:00:00

abstract：:Von Willebrand disease (VWD) is the most commonly inherited bleeding disorder, caused by inheritance of a quantitative or qualitative abnormality of von Willebrand factor (VWF). While the majority of patients with VWD are successfully treated with adjunctive therapies or with the synthetic vasopressin analog desmopres...

journal_title：Seminars in hematology

authors： Hambleton J

更新日期：2001-10-01 00:00:00

abstract：:Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the ...

journal_title：Seminars in hematology

authors： La Rosée P,Deininger MW

更新日期：2010-10-01 00:00:00

abstract：:Hereditary hemochromatosis is one of the most common inherited disorders among Caucasians of European ancestry. Malregulation of iron absorption from the duodenum eventually leads to iron overload. Although the time required to become iron loaded is variable, it is clear that most homozygotes will eventually become sy...

journal_title：Seminars in hematology

authors： Edwards CQ,Griffen LM,Ajioka RS,Kushner JP

更新日期：1998-01-01 00:00:00

abstract：:Myelofibrosis with myeloid metaplasia, also known as idiopathic myelofibrosis (IF) or agnogenic myeloid metaplasia, is one of the characteristic manifestations of polycythemia vera (PV) in the spent phase, and has a particularly adverse prognosis. IF may also present de novo. To date, treatment strategies for both spe...

journal_title：Seminars in hematology

authors： Fruchtman SM

更新日期：2003-01-01 00:00:00

abstract：:These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to ident...

journal_title：Seminars in hematology

authors： Koeffler HP

更新日期：1996-04-01 00:00:00

abstract：:For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

journal_title：Seminars in hematology

authors： Sebastian Schäfer H,Finke J

更新日期：2016-04-01 00:00:00

abstract：:Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

journal_title：Seminars in hematology

authors： Chai SJ,Macik BG

更新日期：2002-07-01 00:00:00

abstract：:Familial thrombosis has long been considered as an autosomal dominant trait, caused by a dominant gene defect with a reduced penetrance for the disease. Recently, this view has changed and today familial thrombophilia is considered as a complex genetic disorder caused by the segregation of two or more gene defects (kn...

journal_title：Seminars in hematology

authors： Koeleman BP,Reitsma PH,Bertina RM

更新日期：1997-07-01 00:00:00

abstract：:Patients with acute myeloid leukemia (AML) who achieve complete remission after induction therapy require post remission therapy (PRT) in order to remain disease free. The role of autologous hematopoietic cell transplantation (autoHCT) in the PRT setting is controversial and is largely based on older trials that were ...

journal_title：Seminars in hematology

authors： Yeshurun M,Wolach O

更新日期：2019-04-01 00:00:00

abstract：:Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

journal_title：Seminars in hematology

authors： Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

更新日期：2010-07-01 00:00:00

abstract：:TET2 is one of the most frequently mutated genes in myeloid neoplasms. TET2 loss-of-function perturbs myeloid differentiation and causes clonal expansion. Despite extensive knowledge regarding biochemical mechanisms underlying distorted myeloid differentiation, targeted therapies are lagging. Here we review known bioc...

journal_title：Seminars in hematology

authors： Guan Y,Hasipek M,Tiwari AD,Maciejewski JP,Jha BK

更新日期：2021-01-01 00:00:00

abstract：:Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

journal_title：Seminars in hematology

authors： Ho AD,Hensel M

更新日期：2006-04-01 00:00:00

abstract：:Mantle-cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells characterized by a nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B-cell phenotype and coexpression of CD5. Two cytologic variants have been identified, typical and blasti...

journal_title：Seminars in hematology

authors： Campo E,Raffeld M,Jaffe ES

更新日期：1999-04-01 00:00:00

abstract：:The antiviral and antigrowth activity of interferon (IFN) makes this agent a promising approach to cancer therapy. Three tumors that are unusually sensitive to IFN-a are chronic myelogenous leukemia (CML) in the benign phase, hairy-cell leukemia, and the T-cell lymphomas associated with mycosis fungoides. Studies usin...

journal_title：Seminars in hematology

authors： Gutterman JU

更新日期：1988-07-01 00:00:00

abstract：:A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

journal_title：Seminars in hematology

authors： Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

更新日期：2001-04-01 00:00:00

abstract：:By definition, myeloproliferative disorders (MPDs) are caused by an acquired somatic mutation of a hematopoietic progenitor/stem cell and have sporadic occurrence. However, well-documented families exist with first-degree relatives acquiring one or several MPDs. It is reasonable to assume that the germ-line mutation(s...

journal_title：Seminars in hematology

authors： Skoda R,Prchal JT

更新日期：2005-10-01 00:00:00

abstract：:In this review, we discuss disease-causing alterations of RUNT-related transcription factor 1 (RUNX1), a master regulator of hematopoietic differentiation. Familial platelet disorder with predisposition to myeloid leukemia (FPDMM) typically presents with (1) mild to moderate thrombocytopenia with normal-sized platelet...

journal_title：Seminars in hematology

authors： Schlegelberger B,Heller PG

更新日期：2017-04-01 00:00:00